These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical trials with immunotherapy for high-grade glioma. Ruzevick J; Jackson C; Phallen J; Lim M Neurosurg Clin N Am; 2012 Jul; 23(3):459-70. PubMed ID: 22748658 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for glioma: promises and challenges. Han SJ; Zygourakis C; Lim M; Parsa AT Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of immunomodulation in human glioblastoma. Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
8. Current concepts in immunotherapy for the treatment of colorectal cancer. Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689 [TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors]. Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858 [TBL] [Abstract][Full Text] [Related]
10. [Antitumor immunity and cellular cancer therapies]. Catros-Quemener V; Bouet F; Genetet N Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191 [TBL] [Abstract][Full Text] [Related]
11. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535 [TBL] [Abstract][Full Text] [Related]
12. Development of vaccines against self-antigens: the p53 paradigm. Chada S; Mhashilkar A; Roth JA; Gabrilovich D Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451 [TBL] [Abstract][Full Text] [Related]
13. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients? Van Gool S; De Vleeschouwer S Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731 [No Abstract] [Full Text] [Related]